Adequate therapy against low-dose aspirin-induced ulcer: comparison of two acid-inhibitory drugs, rabeprazole and famotidine (Quality study)

Adequate therapy against low-dose aspirin-induced ulcer: comparison of two acid-inhibitory drugs, rabeprazole and famotidine (Quality study) - Quality study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007639

Enrollment

200

Registered

2012-04-02

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric ulcer during usage of low dose aspirin (80-100 mg/day)

Interventions

rabeprazole sodium famotidine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients of 20 years or older 2. Patients taking low-dose aspirin more than 4 weeks 3. Patients who will take low-dose aspirin at least 8 weeks 4. Patients with written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients with allergy for rabeprazole and famotidine 2. Patients who have taken endoscopic banding 3. Patients who have taken digestive surgical procedure 4. Patients under treatment of atazanavir sulfate 5. Patients who have taken proton pomp inhibiter within 2 weeks before endoscopy 6. Patients who have taken NSAIDS or steroid 7. Patients who have malignant neoplasm or serious disease

Design outcomes

Primary

Measure	Time frame
Improvement of endscopic finding 4 weeks and 8 weeks after initiating rabeprazole or famotidine	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026